Prostate cancer vaccine developer loses chief executive

Anonymous

Guest
Is he coming to Dendreon?

San Francisco Business Times
Reiner Laus, president of Bavarian Nordic A/S's cancer vaccines division and head of BN ImmunoTherapeutics in Mountain View, left the company Tuesday during an ongoing late-stage trial of its experimental prostate cancer vaccine.

The Denmark-based parent company did not provide more details about the circumstances that led to Laus' departure. It said the search for his replacement is expected to conclude soon.

Laus, who was the fourth employee at Dendreon Corp. (NASDAQ: DNDN), the Seattle developer of the Provenge prostate cancer vaccine, had headed BN ImmunoTherapeutics since 2005. He helped develop the company's clinical pipeline, most significantly Prostvac, which is in a Phase III trial in prostate cancer.

BN started its 1,200-patient Phase III trial in November 2011. The study is expected to fully enroll by the end of 2013. Data would read out in late 2015.
 


















Dr. Gold was given a new 3 year contract to be CEO 3 months after the occurrences of August 3, 2011. The date of the contract was November 15, 2011.

Here are some important parts of that contract:

"EMPLOYMENT AGREEMENT

This Agreement is made, entered into, and is effective as of the Effective Date, by and between the Company and the Executive."

2.17 “Effective Date” means January 31, 2012.
2.19 “Employment Date” means January 31, 2012."

Dr. Gold resigned the CEO position on the effective date of the contract. In other words, he resigned the CEO position on January 31, 2012.

Dendreon agreed to keep this same contract in full force except for a few amendments involving changing his employment duties from CEO to just serving on the BoD. One of the amendments was the following:

"If the Company intends to issue any press releases that refer specifically to Employee, the Company will provide Employee an opportunity to review such press release in advance of its release, and the Company will consider in good faith any comments to such press release that Employee may provide."

In conclusion, a decision was made to give Dr. Gold a 3 year CEO contract after the occurrences of August 3, 2011 and then another decision was made that allowed him to resign on the effective date of the contract while keeping the original contract in full force except for a few amendments relating to his change in employment duties and other details like the right to review potential press releases. The salary remains the same as outlined in the original agreement at 800k a year.
 






No details in a suprisingly timed move like this Laus departure can mean it is information that can't be made public.

If he indeed is coming to Dendreon as part of a cleanup that could include other issues/announcements, any news on where he might be going would not be made public if the intent is to announce everything simultaneously.
 












A decision was made to give Dr. Gold a 3 year CEO contract after the occurrences of August 3, 2011 and then another decision was made that allowed him to resign on the effective date of the contract while keeping the original contract in full force except for a few amendments relating to his change in employment duties and other details like the right to review potential press releases. The salary remains the same as outlined in the original agreement at 800k a year.

This is so obstructive. Gives credence to all those posts saying he was being harbored. Why the hell else would they have such a dysfunctional agreement that is such a terrible act of deceipt to employees, owners and the best interest of cancer patients. Evil to the core.
 












Maybe part of a cleanup hopefully.

Timeline-

Post on Cafe Pharma - 1-20-2013

"Rick Hamm and Dendreon always knew this cost 93k over 4-6 weeks and had to be fronted by providers. This is a first of its kind dynamic in any drug launch

If Rick Hamm thinks he can just write generic risk factors that would apply for almost any drug launch and not include very specific rick factors for a first of its kind "paradigm shift" then his Harvard Law and Wharton Business Education were a pathetic waste. His sudden and mysterious resignation shortly before the August 3, 2011 disaster leave all kinds of questions."

San Francisco Business Times - 1-22-13

"Reiner Laus, president of Bavarian Nordic A/S's cancer vaccines division and head of BN ImmunoTherapeutics in Mountain View, left the company Tuesday during an ongoing late-stage trial of its experimental prostate cancer vaccine.

The Denmark-based parent company did not provide more details about the circumstances that led to Laus' departure. Laus also declined to comment."
 






No details in a suprisingly timed move like this Laus departure can mean it is information that can't be made public.

If he indeed is coming to Dendreon as part of a cleanup that could include other issues/announcements, any news on where he might be going would not be made public if the intent is to announce everything simultaneously.


I thought they were bringing in the VP of Furniture Liquidators to help sell all the extra crap. That was the big win recently.
 












My understanding is that Dr. Reiner Laus left Bavaraian Nordic to undertake psychiatric training so that he can treat your case of paranoid psychosis.

If you believe that Dr. Reiner leaving BN is not connected to events at Dendreon, you should state it and why you think its a coincidence.

Your name calling and insults here for over a year about mental illness illustrates to everyone (if you work at the company) the levels this company stoops to or (if you don't work at the company) the cultist blind fanaticism of its shareholders.
 






Timeline-

Post on Cafe Pharma - 1-20-2013

"Rick Hamm and Dendreon always knew this cost 93k over 4-6 weeks and had to be fronted by providers. This is a first of its kind dynamic in any drug launch

If Rick Hamm thinks he can just write generic risk factors that would apply for almost any drug launch and not include very specific rick factors for a first of its kind "paradigm shift" then his Harvard Law and Wharton Business Education were a pathetic waste. His sudden and mysterious resignation shortly before the August 3, 2011 disaster leave all kinds of questions."

San Francisco Business Times - 1-22-13

"Reiner Laus, president of Bavarian Nordic A/S's cancer vaccines division and head of BN ImmunoTherapeutics in Mountain View, left the company Tuesday during an ongoing late-stage trial of its experimental prostate cancer vaccine.

The Denmark-based parent company did not provide more details about the circumstances that led to Laus' departure. Laus also declined to comment."

Dr. Laus waas at BN since 2005. Just a coincidence, though, that he left 2 days after that Cafe Pharma post. It's also normal that a company would not give any comment and when the employee was asked for a comment he didn't have one either.

All just random and happenstance!!
 







Write your reply...